Abstrait

Treatment of Dementia in Parkinsonian Patients

Felix-Martin Werner* and Rafael Coveñas

Among the patients with Parkinson’s disease, 85% show symptoms of a mild cognitive impairment and 40% develop criteria of dementia. Increased levels of glutamate, noradrenaline and serotonin can be found. Diagrams of neural pathways in the extrapyramidal system and hippocampus and temporal cortex are described and compatible treatments for both syndromes are derived. Besides a conventional treatment with the cholinesterase inhibitor, NMDA antagonists, in combination with a decarboxylase inhibitor and selegeline could be administered additionally.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié